Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader

Overview of attention for article published in EJNMMI Research, June 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 22 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

COMBINATION COMPRISING RIBOCICLIB AND AMCENESTRANT

Application WO-2022218956-A1

World Intellectual Property Organisation (WIPO)

TREATMENT OF BREAST CANCER WITH AMCENESTRANT AND PALBOCICLIB

Application WO-2022187392-A1

World Intellectual Property Organisation (WIPO)

PANEL OF ER REGULATED GENES FOR USE IN MONITORING ENDOCRINE THERAPY IN BREAST CANCER

Application WO-2022109395-A3

World Intellectual Property Organisation (WIPO)